Strongest evidence
Outcomes with moderate evidence strength include: reduced interleukin-6 levels (3 of 5 studies beneficial, moderate effect, 1000 mg/day), reduced systolic blood pressure (4 of 4 studies beneficial, moderate effect, estimated 3.7 mmHg reduction), and reduced complex regional pain syndrome (3 of 3 studies beneficial, small effect, 1 g/day for ~40 days in surgical patients). All three have consistent direction across studies.
Mixed or weaker evidence
Outcomes with low evidence strength include: reduced mortality risk (1 of 5 studies beneficial in COVID-19, 4 neutral in sepsis), reduced oxidative stress (3 of 4 beneficial, but based on small samples), reduced pain (3 of 4 beneficial, moderate effect), improved lung function (2 of 4 beneficial, mixed), reduced tumor necrosis factor alpha (2 of 4 beneficial), reduced diastolic blood pressure (2 of 3 beneficial), and reduced length of hospital stay (0 of 3 beneficial, all neutral). Many of these studies had small sample sizes, short durations, or populations that limit generalizability.
Effective dose patterns
Across outcomes, the most frequently studied dose is 1000 mg/day — used in interleukin-6, complex regional pain syndrome, oxidative stress, and some TNF-α studies. For blood pressure outcomes, doses were less consistently reported, but effects appeared at 250–1000 mg/day. One lung function trial used 500 mg/day. No clear dose-response relationship could be established for pain or mortality due to variability.
Population insights
Nearly all evidence comes from clinical populations — patients with cardiac surgery, sepsis, type 2 diabetes, kidney disease, sarcopenia, knee arthroplasty, or COVID-19. Healthy adults were rarely the focus, which means conclusions may not apply to general wellness use. Benefits for blood pressure were more pronounced in people with elevated baseline values, and anti-inflammatory effects (IL-6, TNF-α) appeared primarily in those with existing inflammatory conditions.
Notable caveats
- Small evidence base: Most outcomes rest on 3–5 studies total; conclusions are preliminary.
- Publication bias: Many syntheses flagged that null-result studies are less likely to be published, especially for positive findings.
- Combination therapy: Several studies used vitamin C with thiamine, hydrocortisone, whey protein, or vitamin E, making it impossible to isolate vitamin C's standalone effect.
- Short durations: Mortality studies averaged only 4 days; long-term outcomes are rarely assessed.
- Statistical significance: Many included studies did not reach significance, even when the direction was beneficial — true effects may be smaller than reported.